

DT14.F PCT/PTO 13 JAN 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on the date shown below:

January 5, 2004

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney



INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. BB-117
Serial No. 10/507,463

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Selwood, Marianne Loehr, Ian Zachary
Serial No. : ~~10/507,463~~ 10/506,598
Art Unit : Not yet assigned
Conf. No. : Not yet assigned
Filed : September 10, 2004
For : VEGF Peptides and Their Use

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the international search report and copies of the references cited therein have been made available in the national stage file; however, for the Examiner's convenience, the applicants are attaching herewith a copy of the references and International Search Report. A form PTO/SB/08 listing the references is also attached. In accordance with 37 CFR §1.56, the applicants hereby request that the references cited in the international search report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, Florida 32614-2950

DRS/lj

Attachment: Form PTO/SB/08
Copies of References cited on Form PTO/SB/08; and
Copy of International Search Report.



Please type a plus sign (+) in the box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/506,598		
		Filing Date	September 2, 2004		
		First Named Inventor	Andreas Meisel		
		Group Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	1	of	2	Attorney Docket Number	BB-117

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1					
	U2					
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Code ⁵ Office (known)	Number ⁴	Kind (if known)			
	F1		WO 9612500	A	Boehringer Ingelheim International	05-02-1996	
	F2		WO 0110465	A	Bayer AG	02-15-2001	
	F3						
	F4						
	F5						
	F6						
	F7						
	F8						

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/506,598
		Filing Date	September 2, 2004
		First Named Inventor	Andreas Meisel
		Group Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	BB-117	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ALLEWELT M <i>et al.</i> , "Diagnosis and Therapy of Abscess Forming Pneumonia" <i>Therapeutische Umschau. Revue Therapeutique.</i> (2001), vol. 58, pages 599-603.	
	R2	"Application of a new fluoroquinolone, moxifloxacin (Avalox®) for the treatment of chronic bronchitis" <i>Notfall Medizin</i> (1999), Germany, vol. 25, page 478, XP009013170.	
	R3	CHRYSOS G E <i>et al.</i> , "Hospital infections in diabetic patients with cerebral stroke" <i>International Journal of Antimicrobial Agents</i> (2001), vol. 17, page S72, XP001152998.	
	R4	GIROIR BP <i>et al.</i> , "Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis" <i>The Lancet</i> (1997), vol. 350, pages 1439-1443.	
	R5	Database WPI, Section Ch, Week 199908 Derwent Publications Ltd., London, GB; Class B04, AN 1999-081970 XP002246596 & CN 1194828 A (WANG W).	
	R6	DAVENPORT R J <i>et al.</i> , "Complications after acute stroke" <i>Stroke Online</i> , vol. 27, pages 415-420, XP002246595.	
	R7	FONG I W, "Antibiotics Effects in a Rabbit Model of Chlamydia pneumoniae-Induced Atherosclerosis" <i>The Journal of Infectious Diseases</i> (2000), United States, vol. 181, pages S514-S518, XP009013134.	
	R8	MARTYNOV YU S <i>et al.</i> , "Early and late post stroke pneumonias" <i>Zhurnal nevrologii i Psikiatrii Imeni S S Korsakova</i> , vol. 80, pages 1628-1634, XP009013167.	
	R9	PANELLA P <i>et al.</i> , "Monitoring of low urinary tract infections in patients hospitalized with neurological diseases" <i>Archivio Italiano di Urologia, Andrologia: Organo Ufficiale di Societa Italiana di Ecografia Urologica E Nefrologica/Associazione Ricerche in Urologia</i> , Italy, December 1994. vol. 66, 259-264, XP009013147.	
	R10	YRJANHEIKKI J <i>et al.</i> , "A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window" <i>Proceedings of the National Academy of Sciences of the United States</i> (1999), vol. 96, pages 13496-13500, XP002246594.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M:\Linda\DOC\IDS\BB-117-IDS.doc\DNB\j

BEST AVAILABLE COPY